image
Healthcare - Medical - Devices - NYSE - IE
$ 212.76
0.0706 %
$ 20.9 B
Market Cap
34.15
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one STE stock under the worst case scenario is HIDDEN Compared to the current market price of 213 USD, STERIS plc is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one STE stock under the base case scenario is HIDDEN Compared to the current market price of 213 USD, STERIS plc is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one STE stock under the best case scenario is HIDDEN Compared to the current market price of 213 USD, STERIS plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart STE

image
$235.0$235.0$230.0$230.0$225.0$225.0$220.0$220.0$215.0$215.0$210.0$210.0$205.0$205.0$200.0$200.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
5.14 B REVENUE
3.65%
836 M OPERATING INCOME
211.77%
380 M NET INCOME
259.20%
973 M OPERATING CASH FLOW
28.58%
-887 M INVESTING CASH FLOW
-131.49%
-85.2 M FINANCING CASH FLOW
82.92%
1.37 B REVENUE
3.13%
245 M OPERATING INCOME
11.67%
173 M NET INCOME
14.63%
333 M OPERATING CASH FLOW
32.75%
-124 M INVESTING CASH FLOW
-17.61%
-214 M FINANCING CASH FLOW
-18.47%
Balance Sheet STERIS plc
image
Current Assets 2.87 B
Cash & Short-Term Investments 207 M
Receivables 1.01 B
Other Current Assets 1.65 B
Non-Current Assets 8.19 B
Long-Term Investments 0
PP&E 1.94 B
Other Non-Current Assets 6.26 B
9.11 %14.95 %17.52 %56.55 %Total Assets$11.1b
Current Liabilities 931 M
Accounts Payable 252 M
Short-Term Debt 117 M
Other Current Liabilities 562 M
Non-Current Liabilities 3.82 B
Long-Term Debt 3.27 B
Other Non-Current Liabilities 551 M
5.30 %11.84 %68.78 %11.61 %Total Liabilities$4.7b
EFFICIENCY
Earnings Waterfall STERIS plc
image
Revenue 5.14 B
Cost Of Revenue 2.92 B
Gross Profit 2.22 B
Operating Expenses 1.4 B
Operating Income 836 M
Other Expenses 456 M
Net Income 380 M
6b6b5b5b4b4b3b3b2b2b1b1b005b(3b)2b(1b)836m(456m)380mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
43.17% GROSS MARGIN
43.17%
16.27% OPERATING MARGIN
16.27%
7.36% NET MARGIN
7.36%
6.00% ROE
6.00%
3.42% ROA
3.42%
6.42% ROIC
6.42%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis STERIS plc
image
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00201620162017201720182018201920192020202020212021202220222023202320242024
Net Income 380 M
Depreciation & Amortization 565 M
Capital Expenditures -360 M
Stock-Based Compensation 56.5 M
Change in Working Capital -146 M
Others 853 M
Free Cash Flow 613 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets STERIS plc
image
Wall Street analysts predict an average 1-year price target for STE of $250 , with forecasts ranging from a low of $225 to a high of $265 .
STE Lowest Price Target Wall Street Target
225 USD 5.75%
STE Average Price Target Wall Street Target
250 USD 17.50%
STE Highest Price Target Wall Street Target
265 USD 24.55%
Price
Max Price Target
Min Price Target
Average Price Target
270270260260250250240240230230220220210210200200190190May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
0.28% DIVIDEND YIELD
0.57 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
2.502.502.002.001.501.501.001.000.500.500.000.000.230.250.280.310.340.370.40.430.470.520.570.230.250.280.310.340.370.40.430.470.520.250.280.310.340.370.40.430.470.520.570.250.960.281.060.311.180.341.300.371.420.41.540.431.660.471.800.521.980.572.180.572015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 14
6. Ownership
Insider Ownership STERIS plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
366 K USD 1
6-9 MONTHS
11.6 M USD 2
9-12 MONTHS
12.9 M USD 8
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy' Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. seekingalpha.com - 3 weeks ago
Steris (STE) Up 3% Since Last Earnings Report: Can It Continue? Steris (STE) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Steris (STE) International Revenue in Focus: Trends and Expectations Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects. zacks.com - 2 months ago
STERIS plc (STE) Q3 2025 Earnings Call Transcript STERIS plc (NYSE:STE ) Q3 2025 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Julie Winter – Investor Relations Mike Tokich – Senior Vice President and Chief Financial Officer Dan Carestio – President and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Brett Fishbin – KeyBanc Michael Polark – Wolfe Research Jason Bednar – Piper Sandler Patrick Wood – Morgan Stanley Mike Matson – Needham & Company Dave Turkaly – Citizens Operator Good day, and welcome to the STERIS plc Third Quarter 2025 Conference Call. All participants will be in a listen-only mode. seekingalpha.com - 2 months ago
STE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket STERIS' third-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The lowered revenue guidance for fiscal 2025 is concerning. zacks.com - 2 months ago
Steris (STE) Reports Q3 Earnings: What Key Metrics Have to Say Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. zacks.com - 2 months ago
Steris (STE) Matches Q3 Earnings Estimates Steris (STE) came out with quarterly earnings of $2.32 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $2.22 per share a year ago. zacks.com - 2 months ago
Steris lowers annual profit forecast due to a stronger dollar Medical equipment maker Steris lowered its annual profit forecast on Wednesday, citing the impact of a stronger dollar. reuters.com - 2 months ago
STERIS Announces Financial Results for Fiscal 2025 Third Quarter DUBLIN, IRELAND, Feb. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 third quarter ended December 31, 2024. Total revenue from continuing operations for the third quarter of fiscal 2025 increased 6% to $1.4 billion compared with $1.3 billion in the third quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the third quarter also increased 6%. globenewswire.com - 2 months ago
Can Steris (STE) Keep the Earnings Surprise Streak Alive? Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com - 2 months ago
Can These 5 MedTech Stocks Hit Earnings Targets This Season? Here is a sneak peek into how five MedTech stocks, BSX, HOLX, TECH, STE and ALGN, are expected to fare in their quarterly results, slated to be released tomorrow. zacks.com - 2 months ago
Wall Street's Insights Into Key Metrics Ahead of Steris (STE) Q3 Earnings Get a deeper insight into the potential performance of Steris (STE) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. zacks.com - 2 months ago
8. Profile Summary

STERIS plc STE

image
COUNTRY IE
INDUSTRY Medical - Devices
MARKET CAP $ 20.9 B
Dividend Yield 0.28%
Description STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Contact 70 Sir John Rogerson's Quay, Dublin, D02 R296 https://www.steris.com
IPO Date June 1, 1992
Employees 18000
Officers Ms. Julia K. Madsen Senior Vice President & GM of Life Sciences Mr. Andrew Xilas Senior Vice President & GM of Dental Mr. Kenneth E. Kohler Senior Vice President & GM of AST Ms. Julie Winter Vice President of Investor Relations & Corporate Communications Mr. Michael J. Tokich Senior Vice President & Chief Financial Officer Ms. Mary Clare Fraser SVice President & Chief Human Resources Officer Mr. Daniel A. Carestio President, Chief Executive Officer & Director Mr. Cary L. Majors Senior Vice President & President of Healthcare Mr. John Adam Zangerle Senior Vice President, General Counsel & Secretary Ms. Karen L. Burton Vice President & Chief Accounting Officer